Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode (TM) Whole ...

The origin of many diseases begins at the cellular level and involves multiple molecular interactions. However, previous methods have struggled to accurately observe changes in individual cells.

Collaboration pairs robust synthetic biology platform with massive scale single cell sequencing to overcome long-standing challenges in variant mapping Parse Biosciences, the leading provider of ...

A wave of spatial transcriptomics studies has produced gene-expression atlases that span entire organs and whole organisms, ...

Rare cancers encompass a heterogeneous group of malignancies characterized by low incidence and prevalence but, often, disproportionately high mortality ...

Ampullary adenocarcinoma: What is the best approach? Insights from a large retrospective series. Evaluating the efficacy of tyrosine kinase inhibitors and other targeted therapies in ...

X-Cell generalizes to new biological contexts and breaks barriers as the first scaling law demonstrator in the virtual cell domain.

Outcomes of young-onset colorectal cancer vs late-onset colorectal cancer patients on phase 1 matched and non-matched therapies. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.